ImmunID to Collaborate with IRX Therapeutics on Test to Predict Immunotherapy Response | GenomeWeb

NEW YORK (GenomeWeb) – ImmunID announced today that it is working with IRX Therapeutics, a clinical-stage cancer immunotherapy developer, to predict response to IRX's investigational drug IRX-2.

Under the terms of the collaboration, ImmunID will use its ImmunTracker technology to assess the immune-modulatory effect of IRX-2 in a randomized phase 2b study of patients with newly diagnosed head and neck squamous cell cancer. The trial is designed to determine whether neoadjuvant treatment with IRX-2 — before an attempt at curative surgery — can reduce the risk of later recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.